Faculty
Brian Van Tine.jpg

Brian A. Van Tine, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Medical Oncology

Clinical Interests

  • Soft tissue and bone sarcomas

Research Interests

  • Human-in-mouse sarcoma models
  • Amino acid deprivation therapies
  • Metabolic deficiencies in sarcoma

Contact

  • 314-362-7997 (tel)
  • 314-362-7086 (fax)
  • 4515 McKinley Research Building, Room 3302 (office)
  • Division of Oncology
    Campus Box 8069
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Publications

  • Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review
    Oppelt PJ, Hirbe AC, Van Tine BA
    J Gastrointest Oncol 2017 Jun;8(3):466-473
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
    Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schoffski P
    Lancet Oncol 2017 Jun 23; [Epub ahead of print]
  • Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect
    Kremer JC, Van Tine BA
    Mol Cell Oncol 2017 Mar 1;4(3):e1295131
  • Neoadjuvant ifosfamide and epirubicin in the treatment of malignant peripheral nerve sheath tumors
    Hirbe AC, Cosper PF, Dahiya S, Van Tine BA
    Sarcoma 2017;2017:3761292
  • Melorheostosis: exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS
    Whyte MP, Griffith M, Trani L, Mumm S, Gottesman GS, McAlister WH, Krysiak K, Lesurf R, Skidmore ZL, Campbell KM, Rosman IS, Bayliss S, Bijanki VN, Nenninger A, Van Tine BA, Griffith OL, Mardis ER
    Bone 2017 Aug;101:145-155
  • Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers
    Kremer JC, Prudner BC, Lange SE, Bean GR, Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K, Shelton L, Li A, Morgan Z, Bomalaski JS, Tsukamoto T, McConathy J, Michel LS, Held JM, Van Tine BA
    Cell Rep 2017 Jan 24;18(4):991-1004
  • A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
    Agulnik M, Costa RLB, Milhem M, Rademaker AW, Prunder BC, Daniels D, Rhodes BT, Humphreys C, Abbinanti S, Nye L, Cehic R, Polish A, Vintilescu C, McFarland T, Skubitz K, Robinson S, Okuno S, Van Tine BA
    Ann Oncol 2017 Jan 1;28(1):121-127
  • A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas
    Bean GR, Kremer JC, Prudner BC, Schenone AD, Yao JC, Schultze MB, Chen DY, Tanas MR, Adkins DR, Bomalaski J, Rubin BP, Michel LS, Van Tine BA
    Cell Death Dis 2016 Oct 13;7(10):e2406
  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK
    Lancet 2016 Jul 30;388(10043):488-97
  • Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma
    Dickson MA, Mahoney MR, Tap WD, D'Angelo SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS, Schwartz GK
    Ann Oncol 2016 Oct;27(10):1855-60
  • PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma
    Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schoffski P
    J Clin Oncol 2016 Sep 12; [Epub ahead of print]
  • Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic
    Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG
    Oncotarget 2016 Jun 7;7(23):33529-41
  • Development of 89Zr-ontuxizumab for in vivo TEM-1/endosialin PET applications
    Lange SE, Zheleznyak A, Studer M, O'Shannessy DJ, Lapi SE, Van Tine BA
    Oncotarget 2016 Mar 15;7(11):13082-13092
  • Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center
    Lange SE, Liu J, Adkins DR, Powell MA, Van Tine BA, Mutch DG
    Gynecol Oncol 2016 Feb;140(2):307-312
  • Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial
    Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
    J Clin Oncol 2016 Mar 10;34(8):786-93
  • A phase Ib/II study of gemcitabine and docetaxel in combination with pazopanib for the neoadjuvant treatment of soft tissue sarcomas
    Munhoz RR, D'Angelo SP, Gounder MM, Keohan ML, Chi P, Carvajal RD, Singer S, Crago AM, Landa J, Healey JH, Qin LX, Hameed M, Ezeoke MO, Singh AS, Agulnik M, Chmielowski B, Luke JJ, Van Tine BA, Schwartz GK, Tap WD, Dickson MA
    Oncologist 2015 Nov;20(11):1245-6
  • The Metastatic Spine Disease Multidisciplinary Working Group algorithms
    Wallace AN, Robinson CG, Meyer J, Tran ND, Gangi A, Callstrom MR, Chao ST, Van Tine BA, Morris JM, Bruel BM, Long J, Timmerman RD, Buchowski JM, Jennings JW
    Oncologist 2015 Oct;20(10):1205-15
  • Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets
    Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA
    Oncotarget 2015 May 20;6(14):12234-47
  • Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma
    D' Angelo SP, Mahoney MR, Van Tine BA, Adkins DR, Perdekamp MT, Condy MM, Luke JJ, Hartley EW, Antonescu CR, Tap WD, Schwartz GK
    Cancer Chemother Pharmacol 2015 Mar;75(3):629-38
  • Using molecular profiling diagnostics to identify predictive biomarkers in metastatic cancer
    Van Tine BA
    MLO Med Lab Obs 2014 Sep;46(9):18, 20-1
  • Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis
    Dong Y, Van Tine BA*, Oyama T, Wang PI, Cheng EH, Hsieh JJ (*co-first author)
    Cell Res 2014 Nov;24(11):1354-66
  • Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC
    Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A, Michel LS
    Oncotarget 2014 Oct 15;5(19):9281-94
  • Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR, Hendifar AE, Kroll S, Ganjoo KN
    J Clin Oncol 2014 Oct 10;32(29):3299-306
  • Novel treatment targets in sarcoma: more than just the GIST
    Shoushtari AN, Van Tine BA, Schwartz GK
    Am Soc Clin Oncol Educ Book 2014:e488-95
  • Current management and molecular targets of synovial sarcoma
    Lange SES, Kremer JC, Schenone AD, Schultze, MB, Van Tine BA
    Austin J Canc Clin Res 2014;1(2):9
  • Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial
    Adenis A, Blay JY, Bui-Nguyen B, Bouche O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blesius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A
    Ann Oncol 2014 Sep;25(9):1762-9
  • Prospective biomarkers for chemotherapy selection in sarcoma
    Schenone AD, Van Tine BA
    ESUN 2014;11(4)
  • Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
    Schenone AD, Luo J, Montgomery L, Morgensztern D, Adkins DR, Van Tine BA
    Cancer Med 2014 Jun;3(3):603-12
  • Gastrointestinal stromal tumors, version 2.2014
    von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H
    J Natl Compr Canc Netw 2014 Jun;12(6):853-62
  • Soft tissue sarcoma, version 2.2014
    von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU 3rd, Delaney TF, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Pappo AS, Paz IB, Pfeifer JD, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Van Tine BA, Wayne JD, Bergman MA, Sundar H
    J Natl Compr Canc Netw 2014 Apr;12(4):473-83
  • BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors
    Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A, Gutmann DH
    Neuro Oncol 2014 Mar;16(3):466-7
  • Novel treatment targets in sarcoma: more than just the GIST
    Shoushtari AN, Van Tine BA, Schwartz GK
    Am Soc Clin Oncol Educ Book 2014:e488-95
  • Novel pathways and molecular targets for the treatment of sarcoma
    Frith AE, Hirbe AC, Van Tine BA
    Curr Oncol Rep 2013 Aug;15(4):378-85
  • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
    Lancet Oncol 2013 Apr;14(4):371-82
  • Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines
    von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, George S, Gonzalez R, Heslin MJ, Kane JM 3rd, Mayerson J, McGarry SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schuetze S, Schupak KD, Schwartz HS, Shankar S, Van Tine BA, Wayne J, Sundar H, McMillian NR
    J Natl Compr Canc Netw 2012 Aug;10(8):951-60
  • Whole-genome analysis informs breast cancer response to aromatase inhibition
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
    Nature 2012 Jun 10;486(7403):353-60
  • A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth
    Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, Cheng EH, Hsieh JJ
    Cancer Res 2012 Feb 1;72(3):736-746
  • ER and PI3K independently modulate endocrine resistance in ER positive breast cancer
    Van Tine BA, Crowder RJ, Ellis MJ
    Cancer Discov 2011 Sep;1(4):287-288
  • Understanding the estrogen receptor-positive breast cancer genome: not even the end of the beginning
    Van Tine BA, Ellis MJ
    J Natl Cancer Inst 2011 Apr 6;103(7):526-7
  • Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis
    Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ
    Cancer Res 2010 Jul 1;70(13):5358-67
  • Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease
    Sadlonova A, Mukherjee S, Bowe DB, Gault SR, Dumas NA, Van Tine BA, Frolova N, Page GP, Welch DR, Novak L, Frost AR
    Am J Pathol 2007 Mar;170(3):1064-76
  • Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development
    Whisenhunt TR, Yang X, Bowe DB, Paterson AJ, Van Tine BA, Kudlow JE
    Glycobiology 2006 Jun;16(6):551-63
  • Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus
    Dao LD, Duffy A, Van Tine BA, Wu SY, Chiang CM, Broker TR, Chow LT
    J Virol 2006 May;80(10):4792-800
  • Clonal selection for transcriptionally active viral oncogenes during progression to cancer
    Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, Meijer CL, Snijders PJ, Chatis P, Broker TR, Moen PT Jr, Chow LT
    J Virol 2004 Oct;78(20):11172-86
  • Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning
    Van Tine BA, Dao LD, Wu SY, Sonbuchner TM, Lin BY, Zou N, Chiang CM, Broker TR, Chow LT
    Proc Natl Acad Sci U S A 2004 Mar 23;101(12):4030-5
  • Identification of exogenous forms of human-tropic porcine endogenous retrovirus in miniature Swine
    Wood JC, Quinn G, Suling KM, Oldmixon BA, Van Tine BA, Cina R, Arn S, Huang CA, Scobie L, Onions DE, Sachs DH, Schuurman HJ, Fishman JA, Patience C
    J Virol 2004 Mar;78(5):2494-501
  • mRNA splicing regulates human papillomavirus type 11 E1 protein production and DNA replication
    Deng W, Jin G, Lin BY, Van Tine BA, Broker TR, Chow LT
    J Virol 2003 Oct;77(19):10213-26
  • Assignment of N-acetyl-D-glucosaminidase (Mgea5) to rat chromosome 1q5 by tyramide fluorescence in situ hybridization (T-FISH): synteny between rat, mouse and human with Insulin Degradation Enzyme (IDE)
    Van Tine BA, Patterson AJ, Kudlow JE
    Cytogenet Genome Res 2003;103(1-2):202B
  • Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes
    Young GD, Winokur TS, Cerfolio RJ, Van Tine BA, Chow LT, Okoh V, Garver RI Jr
    Lung Cancer 2002 May;36(2):133-41
  • Functional analysis of the simian immunodeficiency virus Vpx protein: identification of packaging determinants and a novel nuclear targeting domain
    Mahalingam S, Van Tine B, Santiago ML, Gao F, Shaw GM, Hahn BH
    J Virol 2001 Jan;75(1):362-74
  • Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription
    Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT, Harper JW
    Genes Dev 2000 Sep 15;14(18):2298-313
  • Mother-to-infant transmission of the human immunodeficiency virus during primary infection
    Van Tine BA, Shaw GM, Aldrovandi G
    N Engl J Med 1999 Nov 11;341(20):1548
  • Concordant induction of cyclin E and p21cip1 in differentiated keratinocytes by the human papillomavirus E7 protein inhibits cellular and viral DNA synthesis
    Jian Y, Van Tine BA, Chien WM, Shaw GM, Broker TR, Chow LT
    Cell Growth Differ 1999 Feb;10(2):101-11
  • Human papillomavirus DNA replication compartments in a transient DNA replication system
    Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT
    J Virol 1999 Feb;73(2):1001-9
  • Assignment of human MFNG, manic fringe Drosophila homolog, to 22q13.1 using tyramide fluorescence in situ hybridization (T-FISH)
    Van Tine BA, Knops J, Shaw GM, May WA
    Cytogenet Cell Genet 1999;87(1-2):132-3
  • Characterization of CFTR expression and chloride channel activity in human endothelia
    Tousson A, Van Tine BA, Naren AP, Shaw GM, Schwiebert LM
    Am J Physiol 1998 Dec;275(6 Pt 1):C1555-64
  • Localization of HuC (ELAVL3) to chromosome 19p13.2 by fluorescence in situ hybridization utilizing a novel tyramide labeling technique
    Van Tine BA, Knops JF, Butler A, Deloukas P, Shaw GM, King PH
    Genomics 1998 Nov 1;53(3):296-9
  • Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors
    Azizeh BY, Van Tine BA, Trivedi D, Hruby VJ
    Peptides 1997;18(5):633-41
  • Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists
    Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, Hruby VJ
    Endocrinology 1996 Aug;137(8):3316-22
  • [desHis1, desPhe6, Glu9] glucagon amide: a newly designed "pure glucagon antagonist"
    Azizeh BY, Van Tine BA, Sturm NS, Hutzler, AM, David C, Trivedi D, Hruby VJ
    Bioorganic and Medicinal Chemistry Letters 1995;5:1849-52